Health Canada approves the use of CIBINQO® (abrocitinib) for the treatment of patients 12+ with moderate-to-severe atopic dermatitis

ESC is always pleased to share news of new treatment options, as we know eczema and atopic dermatitis can be complex and challenging to manage. Pfizer Canada ULC announced that Health Canada has approved CIBINQO® (abrocitinib), an oral JAK inhibitor for the treatment of patients with moderate-to-severe atopic dermatitis (AD) in patients 12 years of age or older.

ESC Executive Director Amanda Cresswell-Melville shared with us: “I know first-hand the challenges of managing atopic dermatitis, and the feelings of frustration and defeat that can arise when trying to treat this condition. New options bring hope, and the advancements in research I have seen in the past decade fill me with hope for our community.”

Have questions? Contact ESC at info@growit-big.com